BioSpace News Archive

Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual and Special Meeting of Shareholders that was held today (the “Meeting”).

China Biologic Products Holdings, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the first quarter of 2020.

DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that the DermTech Pigmented Lesion Assay (the “DermTech PLA”) is reviewed in the Journal of the American Academy of Dermatology

Zoetis Inc. (NYSE:ZTS) today announced the results of shareholder voting at its 2020 Annual Meeting of Shareholders and provided details on its third quarter 2020 dividend.

China Biologic Products Holdings, Inc. declared that Xinjiang Deyuan Bioengineering Co., Ltd., China Biologic’s source plasma supplier and cooperation partner, has materially breached its strategic cooperation with China Biologic by entering into plasma supply arrangements with Southern Shuanglin Bio-Pharmacy Co., Ltd., and that China Biologic will take all necessary measures to protect its rights.

The Korean biotech company Macrogen (CEO Sukang Lee) (KOSDAQ: 038290), announced that it obtained export approval for COVID-19 test kit ‘Axen TM COVID-19 RT’ from the Ministry of Food and Drug Safety (MFDS) on the 18 th.

AR Tech, a division of A&R Tarpaulins Inc., an aerospace and medical equipment manufacturer, received emergency approval for the use of its Patient Isolation Transportation Unit (PITU) by the Food and Drug Administration

Actor and Stand Up To Cancer (SU2C) Ambassador Jaime Camil has joined forces with cancer survivors in a new public service announcement (PSA) campaign to raise awareness with the Hispanic community about cancer clinical trials

Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to deliver oxygen to the areas where it is needed most, today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, with certain institutional and accredited investors of 11,428,572

QuantLase Imaging Lab, the medical-research arm of the Abu Dhabi Stock Exchange-listed International Holdings Company (IHC), announced that it has developed novel equipment which enables for much faster mass screenings, with test results available in seconds and allowing testing on a wider scale.